Paving the way for anti-Abeta active immunotherapy
European Pharmaceutical Review
SEPTEMBER 22, 2023
Active immunotherapy through vaccination has a far lower cost than mAb-based therapies, representing an important decrease of economic burden for healthcare systems at a global scale. She has extensive experience in the biopharmaceutical industry and previously served as Chief Scientific Officer for Novimmune from 2005.
97 
Let's personalize your content